In an exchange filing made after market hours on Friday (May 19), the pharmaceutical company said that the United States Food and Drug Administration (US FDA) had conducted a good manufacturing practices (GMP) plus pre-approval inspection of Piramal Pharma's Pithampur facility from 15 May 2023 to 19 May 2023.

The inspection was completed successfully with 'zero' Form - 483 observations and no action indicated (NAI) designation.

"The company remains committed to maintain the highest standards of compliance,” Piramal Pharma said in a statement.

Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide.

The pharmaceutical company reported a consolidated net loss of Rs 90 crore in Q3 December 2022 as against a net profit of Rs 163.37 crore in the year-ago period. Revenue from operations rose by 11% year-on-year to Rs 1,716 crore in Q3 FY23 from Rs 1,539 crore in the year-ago period.